FRANZ WAIBEL

Franz Waibel has over 30 years of experience in the field of value assessment of medicines and medical products and has been involved in matters related to HTA throughout his career. He has worked in a broad range of positions spanning several fields from science and research to managerial business roles, to roles in public affairs and policy as well as to advisory and consulting roles.

Since 2014, he provides services as an independent strategic advisor and consultant on issues related to Patient Access to medicines and medical products, Value Assessment and Value Communication, Health Technology Assessment and Health Policy. He has in addition a keen interest to share and apply his senior leadership experience. He provides trainings on leadership and team development, acts as coach, mentor and mediator and advises on organizational development and change management. He is passionate about strengthening patient involvement in HTA and in Healthcare, and he is also keen to further multi-stakeholder dialogues between the public sector, industry and with involvement of patients and citizens.

He has gained substantial leadership and business management experience through his 25 years corporate career. He has a strong track record in establishing organizational efficiency and effectiveness, leading through transformational change, implementing governance processes and developing young talents. He has led patient access, HTA, HEOR and Public Affairs functions with global, regional and local responsibilities within several corporations including Novartis, Pfizer, Merck&Co, Bayer and Vifor Pharma.

Franz is supporting HTAi and is involved in the society since 2005. He has been serving for a number of years on the HTAi Global Policy Forum. He is an active member of the HTAi Patient and Citizen Involvement IG and has been a member of the HTAi Regulatory Interactions and Conditional Coverage IG. Through his corporate roles he supported and encouraged numerous contributions to HTAi in the form of abstracts, publications, panels and symposia.

He lived and worked in Germany, Belgium, the USA and in Switzerland and has been engaged in healthcare system and HTA policy matters across many jurisdictions in Latin America, North America, Asia and Europe. He has been part of cross stakeholder initiatives at the EU level, he has been engaged in policy discussions across the globe and served on various association working groups, think tanks (e.g. CIRS) and boards (EuropaBio).

Franz studied Cell Biology, Genetics, and Pharmacology and graduated in human genetics at the University of Freiburg, Germany. He holds a PhD in Cell Biology from the University of Basel, Switzerland, and an MBA from the University of Birmingham, UK. In addition, he has completed post-graduate educations in Health Economics and Outcomes Research, various leadership trainings and he is a certified coach and mediator. Franz holds Swiss and German citizenships and lives with his wife in the Basel area in Switzerland.